Basit öğe kaydını göster

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

dc.contributor.authorRoessner, Martin
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorShen, Liji
dc.contributor.authorGupta, Sunil
dc.contributor.authorSartor, A. Oliver
dc.contributor.authorde Bono, Johann Sebastian
dc.contributor.authorOudard, Stephane
dc.contributor.authorHansen, Steinbjorn
dc.contributor.authorMachiels, Jean-Pascal
dc.contributor.authorKocak, Ivo
dc.contributor.authorGravis, Gwenaelle
dc.contributor.authorBodrogi, Istvan
dc.contributor.authorMackenzie, Mary J.
dc.date.accessioned2021-03-03T20:38:02Z
dc.date.available2021-03-03T20:38:02Z
dc.date.issued2010
dc.identifier.citationde Bono J. S. , Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., Gravis G., Bodrogi I., Mackenzie M. J. , Shen L., et al., "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial", LANCET, cilt.376, sa.9747, ss.1147-1154, 2010
dc.identifier.issn0140-6736
dc.identifier.othervv_1032021
dc.identifier.otherav_5aea260e-0db3-4a5a-816e-99be8117b3be
dc.identifier.urihttp://hdl.handle.net/20.500.12627/63859
dc.identifier.urihttps://doi.org/10.1016/s0140-6736(10)61389-x
dc.description.abstractBackground Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment.
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titlePrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
dc.typeMakale
dc.relation.journalLANCET
dc.contributor.departmentRoyal Marsden NHS Foundation Trust , ,
dc.identifier.volume376
dc.identifier.issue9747
dc.identifier.startpage1147
dc.identifier.endpage1154
dc.contributor.firstauthorID44140


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster